Bone health management in patients with breast cancer: Current standards and emerging strategies

Breast

Volumn 21, Issue 1, 2012, Pages 8-19

  Aapro, Matti S ^a   Coleman, Robert E ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Anticancer; Bisphosphonate; Bone metastases; Bone mineral density; Skeletal related event; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ESTROGEN; GOSERELIN; IBANDRONIC ACID; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

AMENORRHEA; BONE; BONE DENSITY; BONE DESTRUCTION; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER TREATMENT INDUCED BONE LOSS; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; FRACTURE; HEART DISEASE; HUMAN; IATROGENIC DISEASE; INFECTION; LONG TERM SURVIVAL; MASTECTOMY; ONCOLOGICAL PARAMETERS; OSTEOLYSIS; OSTEOPENIA; OVERALL SURVIVAL; OVULATION INHIBITION; PATIENT COMPLIANCE; PATIENT SELECTION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SKELETAL RELATED EVENT; TUMOR VOLUME;

EID: 84856345986     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.08.138     Document Type: Review

References (123)

1. Kurian A.W., Clarke C.A., Carlson R.W. The decline in breast cancer incidence: real or imaginary?. Curr Oncol Rep 2009, 11:21-28.
2. Breast cancer facts and figures 2009-2010 2009, American Cancer Society, American Cancer Society, Inc., Atlanta.
3. Sant M., Allemani C., Santaquilani M., Knijn A., Marchesi F., Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009, 45:931-991.
4. Major P.P., Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002, 25:S10-S18.
5. Brufsky A.M., Bosserman L.D., Caradonna R.R., Haley B.B., Jones C.M., Moore H.C., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85.
6. Eidtmann H., de Boer R., Bundred N., Llombart-Cussac A., Davidson N., Neven P., et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010, 21:2188-2194.
7. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., Kainberger F., Kassmann H., Piswanger-Solkner J.C., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849.
8. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, etal. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Presented at: American Society of Clinical Oncology 2009 Breast Cancer Symposium; October 8-10, 2009; San Francisco, CA [Abstract 213].
9. Hadji P., Body J.-J., Aapro M.S., Brufsky A., Coleman R.E., Guise T., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416.
10. Kanis J.A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007, 18:1033-1046.
11. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. NEngl J Med 1995, 332:767-773.
12. Shapiro C.L., Manola J., Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. JClin Oncol 2001, 19:3306-3311.
13. Fogelman I., Blake G.M., Blamey R., Palmer M., Sauerbrei W., Schumacher M., et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003, 14:1001-1006.
14. Gnant M.F., Mlineritsch B., Luschin-Ebengreuth G., Grampp S., Kaessmann H., Schmid M., et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. JClin Oncol 2007, 25:820-828.
15. Coleman R.E., Banks L.M., Girgis S.I., Kilburn L.S., Vrdoljak E., Fox J., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8:119-127.
16. Eastell R., Adams J.E., Coleman R.E., Howell A., Hannon R.A., Cuzick J., et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. JClin Oncol 2008, 26:1051-1057.
17. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
18. Perez E.A., Josse R.G., Pritchard K.I., Ingle J.N., Martino S., Findlay B.P., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. JClin Oncol 2006, 24:3629-3635.
19. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. Acomparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. NEngl J Med 2005, 353:2747-2757.
20. Brufsky A., Harker W.G., Beck J.T., Carroll R., Tan-Chiu E., Seidler C., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. JClin Oncol 2007, 25:829-836.
21. Lester J.E., Dodwell D., Purohit O.P., Gutcher S.A., Ellis S.P., Thorpe R., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342.
22. Saarto T., Blomqvist C., Valimaki M., Makela P., Sarna S., Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997, 75:602-605.
23. Saarto T., Vehmanen L., Blomqvist C., Elomaa I. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. JClin Oncol 2008, 26:4289-4295.
24. Van Poznak C., Hannon R.A., Mackey J.R., Campone M., Apffelstaedt J.P., Clack G., et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. JClin Oncol 2010, 28:967-975.
25. Confavreux C.B., Fontana A., Guastalla J.P., Munoz F., Brun J., Delmas P.D. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007, 41:346-352.
26. Greenspan S.L., Brufsky A., Lembersky B.C., Bhattacharya R., Vujevich K.T., Perera S., et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. JClin Oncol 2008, 26:2644-2652.
27. Singh S., Cuzick J., Edwards R., Blake G., Truscott J., Coleman R., et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). Breast Cancer Res Treat 2007, 106(suppl. 1):S9. [Abstract 28].
28. Cole R.E., Harris S.T. Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. Medscape J Med 2009, 11:12.
29. Cooper A., Drake J., Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006, 60:896-905.
30. Downey T.W., Foltz S.H., Boccuzzi S.J., Omar M.A., Kahler K.H. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006, 99:570-575.
31. Ettinger M.P., Gallagher R., MacCosbe P.E. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006, 12:522-528.
32. Reginster J.Y. Adherence and persistence: impact on outcomes and health care resources. Bone 2006, 38(suppl. 2):S18-S21.
33. Silverman S.L., Gold D.T. Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 2008, 10:118-122.
34. Weiss T.W., Henderson S.C., McHorney C.A., Cramer J.A. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 2007, 23:2193-2203.
35. Mangiapane S., Hoer A., Gothe H., Barghout V., Haeussler B. Higher persistency with i.v. bisphosphonates in patients with bone metastasis. JClin Oncol 2006, 24(suppl.):698s. [Abstract 18623].
36. Brufsky A, Harker G, Beck JT, Carroll R, Jin L, Warsi G, etal. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up. Presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX [Abstract 4083].
37. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. NEngl J Med 2009, 360:679-691.
38. Fuleihan G.E.-H., Salamoun M., Mourad Y.A., Chehal A., Salem Z., Mahfoud Z., et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. JClin Endocrinol Metab 2005, 90:3209-3214.
39. Hershman D.L., McMahon D.J., Crew K.D., Cremers S., Irani D., Cucchiara G., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. JClin Oncol 2008, 26:4739-4745.
40. Hershman D.L., McMahon D.J., Crew K.D., Shao T., Cremers S., Brafman L., et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. JClin Endocrinol Metab 2010, 95:559-566.
41. Hines S.L., Mincey B.A., Sloan J.A., Thomas S.P., Chottiner E., Loprinzi C.L., et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. JClin Oncol 2009, 27:1047-1053.
42. Logman J.F.S., Heeg B.M.S., Botteman M.F., Kaura S., van Hout B.A. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Ann Oncol 2010, 21:1529-1536.
43. Diel I.J., Solomayer E.F., Costa S.D., Gollan C., Goerner R., Wallwiener D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. NEngl J Med 1998, 339:357-363.
44. Powles T., Paterson A., McCloskey E., Schein P., Scheffler B., Tidy A., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
45. Diel I.J., Jaschke A., Solomayer E.F., Gollan C., Bastert G., Sohn C., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008, 19:2007-2011.
46. Saarto T., Blomqvist C., Virkkunen P., Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. JClin Oncol 2001, 19:10-17.
47. Saarto T., Vehmanen L., Virkkunen P., Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
48. Green J.R., Muller K., Jaeggi K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. JBone Miner Res 1994, 9:745-751.
49. Bria E., Nistico C., Cuppone F., Carlini P., Ciccarese M., Milella M., et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006, 106:2337-2344.
50. NCCN clinical practice guidelines in oncology: breast cancer. Version 2.2011 2011, National Comprehensive Cancer Network, Available at:, National Comprehensive Cancer Network, Fort Washington, PA, [accessed 27.06.11]. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
51. Gnant M., Mlineritsch B., Stoeger H., Luschin-Ebengreuth G., Heck D., Menzel C., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12:631-641.
52. Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M, etal. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX [Abstract S4-5].
53. Coleman R., Winter M., Cameron D., Bell R., Dodwell D., Keanne M., et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105.
54. Lin A.Y., Park J.W., Scott J., Melisko M., Goga A., Moasser M.M., et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. JClin Oncol 2008, 26(suppl.):20s. [Abstract 559].
55. Rack B.K., Jueckstock J., Genss E.-M., Schoberth A., Schindlbeck C., Strobl B., et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Breast Cancer Res Treat 2007, 106(suppl. 1):S40. [Abstract 511].
56. Solomayer E.F., Gebauer G., Hirnle P., Janni W., Lück H.-J., Becker S., et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res 2009, 69(suppl.):170s-171s. [Abstract 2048].
57. Aft R., Naughton M., Trinkaus K., Watson M., Ylagan L., Chavez-Macgregor M., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428.
58. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. JClin Oncol 2003, 21:4042-4057.
59. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.-J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
60. Reid D.M., Doughty J., Eastell R., Heys S.D., Howell A., McCloskey E.V., et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008, 34(suppl. 1):S3-S18.
61. Body J.J., Bergmann P., Boonen S., Boutsen Y., Devogelaer J.P., Goemaere S., et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporos Int 2007, 18:1439-1450.
62. Aapro M., Abrahamsson P.A., Body J.J., Coleman R.E., Colomer R., Costa L., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
63. Rochlitz C., Senn H.J., Betticher D., Helbling D., von Moos R., Pestalozzi B., et al. Recommendations of a Swiss expert group on the use of bisphosphonates in patients with solid tumors. Swiss Med Forum 2010, 10:562-564.
64. Aebi S., Davidson T., Gruber G., Castiglione M. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl. 5):v9-v14.
65. Van Poznak C.H., Temin S., Yee G.C., Janjan N.A., Barlow W.E., Biermann J.S., et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. JClin Oncol 2011, 29:1221-1227.
66. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989-995.
67. Kanis J.A., Johansson H., Oden A., Johnell O., De Laet C., Eisman J.A., et al. Afamily history of fracture and fracture risk: a meta-analysis. Bone 2004, 35:1029-1037.
68. Kanis J.A., Johansson H., Oden A., Johnell O., de Laet C., Melton I.L., et al. Ameta-analysis of prior corticosteroid use and fracture risk. JBone Miner Res 2004, 19:893-899.
69. Kanis J.A., Johnell O., De Laet C., Johansson H., Oden A., Delmas P., et al. Ameta-analysis of previous fracture and subsequent fracture risk. Bone 2004, 35:375-382.
70. Kanis J.A., Johnell O., Oden A., Johansson H., De Laet C., Eisman J.A., et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005, 16:155-162.
71. Clinician's guide to prevention and treatment of osteoporosis 2010, National Osteoporosis Foundation, National Osteoporosis Foundation, Washington, DC, Available at:, [accessed 27.06.11]. http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf.
72. Prevention and management of osteoporosis. WHO 2003, 921:1-192. World Health Organization, Technical Report Series.
73. Kanis JA. FRAX® WHO fracture risk assessment tool. Web version 3.2. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; Available at: [accessed 27.06.11]. http://www.shef.ac.uk/FRAX/.
74. Kanis J.A., McCloskey E.V., Powles T., Paterson A.H., Ashley S., Spector T. Ahigh incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79:1179-1181.
75. Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010, 17:25-54.
76. Kelley G.A., Kelley K.S., Tran Z.V. Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data. JGerontol A Biol Sci Med Sci 2002, 57:M599-M604.
77. Swenson K.K., Nissen M.J., Anderson E., Shapiro A., Schousboe J., Leach J. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. JSupport Oncol 2009, 7:101-107.
78. Burgess T.L., Qian Y., Kaufman S., Ring B.D., Van G., Capparelli C., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. JCell Biol 1999, 145:527-538.
79. Ellis G.K., Bone H.G., Chlebowski R., Paul D., Spadafora S., Smith J., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. JClin Oncol 2008, 26:4875-4882.
80. US Department of Health and Human Services. Denosumab safety FDA analysis. Proceedings of the August 13, 2009, meeting of the Reproductive Health Drugs Advisory Committee. Available at: [accessed 27.06.11]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM179782.pdf.
81. Anastasilakis A.D., Toulis K.A., Goulis D.G., Polyzos S.A., Delaroudis S., Giomisi A., et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009, 41:721-729.
82. Toulis K.A., Anastasilakis A.D. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int 2010, 21:1963-1964.
83. Prolia 60 mg solution for injection [summary of product characteristics] 2010, Amgen Europe B.V, Breda, The Netherlands.
84. Prolia™ (denosumab) injection [package insert] 2010, Amgen Inc., Thousand Oaks, CA.
85. [Prolia, injection (denosumab)]. Swiss agency for therapeutic products. Available at: [accessed 27.06.11]. http://www.swissmedic.ch/zulassungen/00171/00181/01382/index.html%3Flang%3Den.
86. Notice of decision for PrProlia™. Health Canada. Available at: [accessed 27.06.11]. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/sbd-smd/phase1-decision/drug-med/nd_ad_2010_prolia_121139-eng.pdf.
87. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 2004, 9(suppl. 4):14-27.
88. Lipton A., Theriault R.L., Hortobagyi G.N., Simeone J., Knight R.D., Mellars K., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in womenwith breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88:1082-1090.
89. Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer 2000, 88:3033-3037.
90. Fitch M., Maxwell C., Ryan C., Lothman H., Drudge-Coates L., Costa L. Bone metastases from advanced cancers: clinical implications and treatment options. Clin J Oncol Nurs 2009, 13:701-710.
91. Abrahm J.L. Assessment and treatment of patients with malignant spinal cord compression. JSupport Oncol 2004, 2:377-388. 91; discussion follows.
92. Loblaw D.A., Perry J., Chambers A., Laperriere N.J. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. JClin Oncol 2005, 23:2028-2037.
93. Saad F., Lipton A., Cook R., Chen Y.-M., Smith M., Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
94. Paterson A.H., Powles T.J., Kanis J.A., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. JClin Oncol 1993, 11:59-65.
95. Pavlakis N., Schmidt R.L., Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005, CD003474.
96. Body J.-J., Diel I.J., Lichinitser M.R., Kreuser E.D., Dornoff W., Gorbunova V.A., et al. Intravenous ibandronate reduces the incidence of skeletal complications inpatients with breast cancer and bone metastases. Ann Oncol 2003, 14:1399-1405.
97. Body J.J., Diel I.J., Lichinitzer M., Lazarev A., Pecherstorfer M., Bell R., et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004, 90:1133-1137.
98. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735-1744.
99. Zheng M, Rosen L, Gordon D, Kaminski M, Howell A, Belch A, etal. Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases. Presented at: The 9th St. Gallen International Consensus Conference on Primary Therapy of Early Breast Cancer; January 26-29, 2005; St. Gallen, Switzerland [Abstract 104].
100. Costa L, Chen Y-M. Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate. Presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX [Abstract 1071].
101. Wong R., Wiffen P.J. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002, CD002068.
102. Kohno N., Aogi K., Minami H., Nakamura S., Asaga T., Iino Y., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. JClin Oncol 2005, 23:3314-3321.
103. Wardley A., Davidson N., Barrett-Lee P., Hong A., Mansi J., Dodwell D., et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005, 92:1869-1876.
104. Body J.-J., Diel I.J., Bell R., Pecherstorfer M., Lichinitser M.R., Lazarev A.F., et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004, 111:306-312.
105. Pendharkar D., Goyal H. Loading dose ibandronate in rapid pain management of metastatic bone disease (MBD). JClin Oncol 2006, 24(suppl.):694s. [Abstract 18580].
106. Heidenreich A., Elert A., Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002, 5:231-235.
107. Mancini I., Dumon J.C., Body J.J. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. JClin Oncol 2004, 22:3587-3592.
108. Winter M.C., Holen I., Coleman R.E. Exploring the anti-tumour activity ofbisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34:453-475.
109. Neville-Webbe H.L., Rostami-Hodjegan A., Evans C.A., Coleman R.E., Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005, 113:364-371.
110. Fontana A., Delmas P.D. Markers of bone turnover in bone metastases. Cancer 2000, 88:2952-2960.
111. Coleman R.E., Major P., Lipton A., Brown J.E., Lee K.A., Smith M., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. JClin Oncol 2005, 23:4925-4935.
112. Lipton A., Cook R.J., Major P., Smith M.R., Coleman R.E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007, 12:1035-1043.
113. Lipton A., Cook R., Saad F., Major P., Garnero P., Terpos E., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
114. De Cock E., Hutton J., Canney P., Body J.J., Barrett-Lee P., Neary M.P., et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther 2005, 27:1295-1310.
115. Guest J.F., Clegg J.P., Davie A.M., McCloskey E. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. Curr Med Res Opin 2005, 21:805-815.
116. Botteman M., Barghout V., Stephens J., Hay J., Brandman J., Aapro M. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006, 17:1072-1082.
117. Paterson A., McCloskey E., Redzepovic J., Ott I., Gust R. Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients. JInt Med Res 2008, 36:400-413.
118. Carter JA, Snedecor SJ, Kaura S, Botteman MF. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC). Presented at: 2011 ASCO Annual Meeting; June 3-7, 2011; Chicago, IL [Abstract 9025].
119. Stopeck A.T., Lipton A., Body J.J., Steger G.G., Tonkin K., de Boer R.H., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. JClin Oncol 2010, 28:5132-5139.
120. Xgeva™ (denosumab) injection [package insert] 2010, Amgen Inc., Thousand Oaks, CA.
121. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, etal. Denosumab to prolong bone metastasis-free survival in men with castrate-resistant prostate cancer: results of a global phase 3, randomized, double-blind trial. Plenary Presentation at: AUA Annual Meeting; May 14-19, 2011; Washington, DC.
122. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. JClin Oncol 2007, 25:486-492.
123. Neville-Webbe H.L., Coleman R.E., Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells invitro: evidence of synergistic interaction. Br J Cancer 2010, 102:1010-1017.